Neo Cremar네오크레마

Neo Cremar's shares have fallen about 71% over the past year, while trailing earnings have turned modestly positive.

Neo Cremar makes microbiome-based functional food materials such as functional sugars and peptides, and through subsidiary BBC also runs materials, healthcare and fashion accessories businesses. For the trailing twelve months to H1 2026 it reported revenue of ₩81.6B, operating income of ₩3.6B and net income of ₩2.3B, with cash of ₩20.3B against borrowings of ₩11.3B. The share price closed at ₩2,315 on 2026-10-22, well below its 52-week high of ₩8,330.

What stands out

• Trailing revenue of ₩81.6B is roughly in line with 2025 full-year revenue of ₩81.9B, and 2025 operating income of ₩5.4B was higher than the trailing ₩3.6B.
• 2024 showed an operating loss and 2023 showed a large net loss of ₩5.0B, so the recent profitability is a recent development rather than a long track record.
• The stock trades at a trailing P/E of 12.6 and P/B of 0.4, with a 2.2% dividend yield, though the data gives no reason for the discount.
• Foreign ownership slipped to 3.4% from 3.7% sixty days earlier, and retail and institutional investors were net sellers over the last 20 days while foreign investors were net buyers.
• Recent filings include a share cancellation decision (2026-09-28), a half-year report (2026-08-14) and 5%+ holding and insider shareholding reports (2026-10-06); the news list for the period is empty.

What to watch

• The next quarterly or annual filings, to see whether operating margin (4.4% trailing) holds up against the 6.6% reached in 2025.
• Details of the share cancellation decision and any effect on the share count of 12.65 million listed shares.
• Debt levels: borrowings of ₩11.3B are well above the ₩20.3B cash balance only in the sense that cash currently exceeds them; the data does not provide the reasons for the sharp price decline.